What is the share price of Divi's Laboratories Ltd (DIVISLAB) today?
The share price of DIVISLAB as on 7th November 2025 is ₹6656.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Divi's Laboratories Ltd (DIVISLAB) share?
The past returns of Divi's Laboratories Ltd (DIVISLAB) share are- Past 1 week: 3.70%
- Past 1 month: 17.95%
- Past 3 months: 8.56%
- Past 6 months: 8.27%
- Past 1 year: 11.69%
- Past 3 years: 94.95%
- Past 5 years: 94.42%
What are the peers or stocks similar to Divi's Laboratories Ltd (DIVISLAB)?
The peers or stocks similar to Divi's Laboratories Ltd (DIVISLAB) include:What is the dividend yield % of Divi's Laboratories Ltd (DIVISLAB) share?
The current dividend yield of Divi's Laboratories Ltd (DIVISLAB) is 0.45.What is the market cap of Divi's Laboratories Ltd (DIVISLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Divi's Laboratories Ltd (DIVISLAB) is ₹176709.16 Cr as of 7th November 2025.What is the 52 week high and low of Divi's Laboratories Ltd (DIVISLAB) share?
The 52-week high of Divi's Laboratories Ltd (DIVISLAB) is ₹7071.50 and the 52-week low is ₹4955.What is the PE and PB ratio of Divi's Laboratories Ltd (DIVISLAB) stock?
The P/E (price-to-earnings) ratio of Divi's Laboratories Ltd (DIVISLAB) is 80.65. The P/B (price-to-book) ratio is 11.81.Which sector does Divi's Laboratories Ltd (DIVISLAB) belong to?
Divi's Laboratories Ltd (DIVISLAB) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Divi's Laboratories Ltd (DIVISLAB) shares?
You can directly buy Divi's Laboratories Ltd (DIVISLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Divi's Laboratories Ltd
DIVISLAB Share Price
6,656.503.30% (-227.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
DIVISLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
DIVISLAB Performance & Key Metrics
DIVISLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 71.11 | 11.81 | 0.45% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.70 | 5.79 | 0.59% |
57%
Analysts have suggested that investors can buy this stock
from 23 analysts
Price Upside
Earnings Growth
Rev. Growth
DIVISLAB Company Profile
Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids.
SYNGENE
PE Ratio
49.89
49.89
1Y Return
32.53%
32.53%
Buy Reco %
83.33
83.33
AARTIPHARM
PE Ratio
28.78
28.78
1Y Return
25.70%
25.70%
Buy Reco %
0.00
0.00
PE Ratio
1,204.18
1,204.18
1Y Return
28.06%
28.06%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
43.52
43.52
1Y Return
127.46%
127.46%
Buy Reco %
0.00
0.00
PE Ratio
74.57
74.57
1Y Return
30.01%
30.01%
Buy Reco %
0.00
0.00
DIVISLAB Sentiment Analysis
DIVISLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
DIVISLAB Stock Summary · August 2025
In Q1 FY2026, the company demonstrated resilience amid ongoing pricing pressures in the global generic market, bolstered by a robust backward integration model and strategic partnerships. The recent launch of the Kakinada facility enhances production capabilities, supporting a balanced focus on generics and custom synthesis, while a strong pipeline of Requests for Proposals is expected to drive growth in the coming years. Despite challenges from geopolitical uncertainties and regulatory hurdles, management remains optimistic about future revenues from new product developments, including peptide-based innovations. The nutraceutical segment is recovering steadily, and long-term contracts provide stability, positioning the company favorably for sustainable growth. Overall, operational excellence and a commitment to green chemistry principles underpin the company’s strategic direction.
DIVISLAB Stock Growth Drivers
DIVISLAB Stock Growth Drivers
6Operational Excellence and Capacity Expansion
The company has made significant strides in operational excellence through digitalization and data-driven decision-making. Strategic
Financial Performance and Growth
In the first quarter of FY 2025-26, the company reported a consolidated total income of
DIVISLAB Stock Challenges
DIVISLAB Stock Challenges
3Flat Performance and Margin Reduction
The company has experienced flat year-over-year performance in its API business, with a notable reduction
Operational Challenges in the Generic Business
The generic business is facing additional costs due to logistical expenses and ongoing shipping issues,
DIVISLAB Forecast
DIVISLAB Forecasts
Price
Revenue
Earnings
DIVISLAB Share Price Forecast
DIVISLAB Share Price Forecast
2025
Current
₹6,656.50
Baseline
Forecast for Nov 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹6,656.50
Baseline
Forecast for Nov 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
DIVISLAB Company Revenue Forecast
DIVISLAB Company Revenue Forecast
2025
Current
₹9.71
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹9.71
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
DIVISLAB Stock EPS (Earnings Per Share) Forecast
DIVISLAB Stock EPS (Earnings Per Share) Forecast
2025
Current
₹82.53
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹82.53
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
DIVISLAB
DIVISLAB
Income
Balance Sheet
Cash Flow
Annual Normal View
DIVISLAB Income Statement
DIVISLAB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,139.23 | 4,004.93 | 5,101.89 | 5,584.05 | 7,031.96 | 9,073.70 | 8,112.17 | 8,184.00 | 9,712.00 | 10,461.00 | ||||||||||
Raw Materials | 1,608.36 | 1,567.94 | 2,169.72 | 2,256.99 | 2,455.40 | 3,552.07 | 3,088.18 | 3,300.00 | 3,890.00 | 6,783.00 | ||||||||||
| Power & Fuel Cost | 198.80 | 228.73 | 248.78 | 280.73 | 319.15 | 392.33 | 496.61 | 477.00 | 465.00 | |||||||||||
| Employee Cost | 499.90 | 456.06 | 542.27 | 621.05 | 825.76 | 946.16 | 975.02 | 1,094.00 | 1,243.00 | |||||||||||
| Selling & Administrative Expenses | 154.26 | 200.48 | 175.70 | 228.23 | 287.84 | 345.20 | 398.36 | 358.00 | 414.00 | |||||||||||
| Operating & Other expenses | 155.88 | 175.53 | -63.23 | 184.21 | 220.08 | -159.07 | 440.23 | 410.00 | 379.00 | |||||||||||
EBITDA | 1,522.03 | 1,376.19 | 2,028.65 | 2,012.84 | 2,923.73 | 3,997.01 | 2,713.77 | 2,545.00 | 3,321.00 | 3,678.00 | ||||||||||
| Depreciation/Amortization | 123.33 | 142.49 | 168.90 | 186.24 | 255.59 | 311.51 | 343.18 | 378.00 | 402.00 | 431.00 | ||||||||||
| PBIT | 1,398.70 | 1,233.70 | 1,859.75 | 1,826.60 | 2,668.14 | 3,685.50 | 2,370.59 | 2,167.00 | 2,919.00 | 3,247.00 | ||||||||||
| Interest & Other Items | 3.36 | 2.37 | 4.68 | 7.14 | 2.10 | 2.00 | 1.96 | 4.00 | 3.00 | 12.00 | ||||||||||
| PBT | 1,395.34 | 1,231.33 | 1,855.07 | 1,819.46 | 2,666.04 | 3,683.50 | 2,368.63 | 2,163.00 | 2,916.00 | 3,235.00 | ||||||||||
| Taxes & Other Items | 334.92 | 354.32 | 502.33 | 442.92 | 681.75 | 723.05 | 545.25 | 563.00 | 725.00 | 750.00 | ||||||||||
| Net Income | 1,060.42 | 877.01 | 1,352.74 | 1,376.54 | 1,984.29 | 2,960.45 | 1,823.38 | 1,600.00 | 2,191.00 | 2,485.00 | ||||||||||
| EPS | 39.95 | 33.04 | 50.96 | 51.85 | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 | 93.61 | ||||||||||
| DPS | 10.00 | 10.00 | 16.00 | 16.00 | 20.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | ||||||||||
| Payout ratio | 0.25 | 0.30 | 0.31 | 0.31 | 0.27 | 0.27 | 0.44 | 0.50 | 0.36 | 0.32 |
DIVISLAB Company Updates
DIVISLAB Stock Peers
DIVISLAB Past Performance & Peer Comparison
DIVISLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Divi's Laboratories Ltd | 80.65 | 11.81 | 0.45% |
| Syngene International Ltd | 49.89 | 5.24 | 0.20% |
| Aarti Pharmalabs Ltd | 28.78 | 3.94 | 0.58% |
| Dishman Carbogen Amcis Ltd | 1,204.18 | 0.67 | — |
DIVISLAB Stock Price Comparison
Compare DIVISLAB with any stock or ETFCompare DIVISLAB with any stock or ETF
DIVISLAB
DIVISLAB Holdings
DIVISLAB Shareholdings
DIVISLAB Promoter Holdings Trend
DIVISLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
DIVISLAB Institutional Holdings Trend
DIVISLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
DIVISLAB Shareholding Pattern
DIVISLAB Shareholding Pattern
DIVISLAB Shareholding History
DIVISLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in DIVISLAB
Mutual Funds Invested in DIVISLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Divi's Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1520% | Percentage of the fund’s portfolio invested in the stock 2.66% | Change in the portfolio weight of the stock over the last 3 months -0.54% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 9/129 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8505% | Percentage of the fund’s portfolio invested in the stock 2.94% | Change in the portfolio weight of the stock over the last 3 months -0.51% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/51 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5511% | Percentage of the fund’s portfolio invested in the stock 2.59% | Change in the portfolio weight of the stock over the last 3 months -0.53% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/33 (-4) |
Compare 3-month MF holding change on Screener
smallcases containing DIVISLAB stock
smallcases containing DIVISLAB stock
Looks like this stock is not in any smallcase yet.
DIVISLAB Events
DIVISLAB Events
DIVISLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DIVISLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.45%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.51 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
DIVISLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DIVISLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.45%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.51 every year
DIVISLAB Upcoming Dividends
DIVISLAB Upcoming Dividends
No upcoming dividends are available
DIVISLAB Past Dividends
DIVISLAB Past Dividends
Cash Dividend
Ex DateEx DateJul 25, 2025
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Jul 25, 2025
Cash Dividend
Ex DateEx DateAug 2, 2024
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Aug 2, 2024
Cash Dividend
Ex DateEx DateAug 11, 2023
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Aug 11, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 17, 2021
Final
Final | Div/Share: ₹20.00
Dividend/Share
₹20.00
Ex DateEx Date
Aug 17, 2021
DIVISLAB Stock News & Opinions
DIVISLAB Stock News & Opinions
Articles & Videos
Earnings
Divi's Laboratories consolidated net profit rises 35.10% in the September 2025 quarter
Net profit of Divi's Laboratories rose 35.10% to Rs 689.00 crore in the quarter ended September 2025 as against Rs 510.00 crore during the previous quarter ended September 2024. Sales rose 16.12% to Rs 2715.00 crore in the quarter ended September 2025 as against Rs 2338.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2715.002338.00 16 OPM %32.7130.62 - PBDT1025.00821.00 25 PBT912.00722.00 26 NP689.00510.00 35 Powered by Capital Market - Live
20 hours agoCapital Market - Live
Earnings
Divi's Laboratories standalone net profit rises 34.36% in the September 2025 quarter
Net profit of Divi's Laboratories rose 34.36% to Rs 696.00 crore in the quarter ended September 2025 as against Rs 518.00 crore during the previous quarter ended September 2024. Sales rose 15.55% to Rs 2660.00 crore in the quarter ended September 2025 as against Rs 2302.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2660.002302.00 16 OPM %33.6531.67 - PBDT1033.00833.00 24 PBT920.00735.00 25 NP696.00518.00 34 Powered by Capital Market - Live
20 hours agoCapital Market - Live
Corporate
Divis Laboratories to announce Quarterly Result
Divis Laboratories will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live
1 week agoCapital Market - Live
Spotlight
Divis Laboratories Ltd soars 1.53%, up for fifth straight session
Divis Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 6573.5, up 1.53% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.31% on the day, quoting at 25205.75. The Sensex is at 82205.85, down 0.36%. Divis Laboratories Ltd has gained around 8.53% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 0.11% in last one month and is currently quoting at 22218.25, down 0.2% on the day. The volume in the stock stood at 6.63 lakh shares today, compared to the daily average of 5.25 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 6588, up 1.38% on the day. Divis Laboratories Ltd is up 5.77% in last one year as compared to a 0.31% jump in NIFTY and a 6.36% jump in the Nifty Pharma index.The PE of the stock is 73.62 based on TTM earnings ending June 25.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Spotlight
Divis Laboratories Ltd down for fifth straight session
Divis Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 5722.5, down 2.96% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.54% on the day, quoting at 24755.4. The Sensex is at 80723.46, down 0.54%.Divis Laboratories Ltd has lost around 6.68% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 1.23% in last one month and is currently quoting at 21977.7, down 1.99% on the day. The volume in the stock stood at 4.33 lakh shares today, compared to the daily average of 3.53 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 5701.5, down 3.58% on the day. Divis Laboratories Ltd jumped 4.85% in last one year as compared to a 5.44% slide in NIFTY and a 8.41% fall in the Nifty Pharma index.The PE of the stock is 67.03 based on TTM earnings ending June 25.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Divis Laboratories Ltd up for third straight session
Divis Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 6247.5, up 1.56% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 24991.1. The Sensex is at 81715.66, up 0.5%. Divis Laboratories Ltd has slipped around 5.11% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has slipped around 1.85% in last one month and is currently quoting at 22265, up 0.34% on the day. The volume in the stock stood at 2.83 lakh shares today, compared to the daily average of 4.49 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 6240, up 1.54% on the day. Divis Laboratories Ltd is up 26.82% in last one year as compared to a 0.08% drop in NIFTY and a 0.95% drop in the Nifty Pharma index.The PE of the stock is 69.89 based on TTM earnings ending June 25.Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Divis Lab gains as broker reiterates buy call
The brokerage downplayed concerns over Eli Lilly's oral GLP-1 candidate Orforglipron and generic risks to Novartis' heart drug Entresto, which contributes about 20% of Divi's consolidated revenue. It expects Divi's to remain a key API supplier, supported by a healthy order pipeline and rising demand in peptides, making the recent stock weakness a buying opportunity. Over the past month, the stock has fallen 7.08% compared with a 0.84% decline in the Sensex. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit rose 26.74% to Rs 545 crore while net sales rose 13.79% to Rs 2410 crore in Q1 June 2025 over Q1 June 2024. Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Divi's Laboratories consolidated net profit rises 26.74% in the June 2025 quarter
Net profit of Divi's Laboratories rose 26.74% to Rs 545.00 crore in the quarter ended June 2025 as against Rs 430.00 crore during the previous quarter ended June 2024. Sales rose 13.79% to Rs 2410.00 crore in the quarter ended June 2025 as against Rs 2118.00 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales2410.002118.00 14 OPM %30.2529.37 - PBDT845.00701.00 21 PBT733.00604.00 21 NP545.00430.00 27 Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Divis Lab slides after Q1 PAT falls 18% QoQ to Rs 545 cr
Revenue from operations also declined 6.79% quarter on quarter (QoQ) to Rs 2,410 crore for the quarter ended 30 June 2025 On a year-on-year (YoY) basis, the company's net profit rose 26.74%, while revenue increased 13.78%, indicating continued growth over the previous year despite the sequential decline. Profit before tax for the quarter stood at Rs 733 crore, down 15.16% QoQ but up 21.35% YoY. The company reported a forex gain of Rs 39 crore during the quarter, compared to a forex loss of Rs 1 crore in the corresponding quarter of the previous financial year. On a standalone basis, the company's net profit surged 29.53% to Rs 557 crore on a 14.25% rise in revenue to Rs 2,357 crore in Q1 FY26 over Q1 FY25. Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Divis Laboratories to table results
Divis Laboratories will hold a meeting of the Board of Directors of the Company on 6 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.7%, vs industry avg of 7.49%
Over the last 5 years, market share increased from 45.83% to 48.92%
Over the last 5 years, net income has grown at a yearly rate of 9.74%, vs industry avg of 8.2%